Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2875478 | 0.84 | NOTUM (0.41) | GAAKDM4EMAPK1RAB9ANPC1 | |
| SCHEMBL2873737 | 0.84 | MAPK1 (0.40) | GAAMAPK1ENPP1MAPTTP53 | |
| SCHEMBL16200078 | 0.83 | MAPT (0.39) | GAASMN1; SMN2KDM4EMAPK1NPSR1 | |
| SCHEMBL16200084 | 0.82 | CYP2A6 (0.41) | SMN1; SMN2ALDH1A1HSD17B10RAB9ANPC1 | |
| SCHEMBL2876798 | 0.82 | NT5E (0.42) | SMN1; SMN2MAPK1MAPTTP53 | |
| SCHEMBL9053226 | 0.80 | GRM5 (0.43) | GAASMN1; SMN2KDM4EMAPK1NPSR1 | |
| SCHEMBL2873684 | 0.79 | ENPP1 (0.44) | KDM4EMAPK1NPSR1ALDH1A1HPGD | |
| SCHEMBL9052069 | 0.79 | KDM4E (0.41) | GAASMN1; SMN2KDM4EMAPK1NPSR1 | |
| SCHEMBL4713606 | 0.79 | KDM4E (0.58) | GAASMN1; SMN2KDM4EMAPK1NPSR1 | |
| SCHEMBL1853386 | 0.79 | KDM4E (0.41) | GAASMN1; SMN2KDM4EMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720545-B1 | BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES | CHEMOCENTRYX INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-7842693-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842693-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1531822-B1 | 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7157464-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1691810-A1 | SUBSTITUTED PIPERAZINES | ChemoCentryx Inc (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1531822-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | Chemocentryx, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040162282-A1 | Substituted piperazines | CHEMOCENTRYX, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20040082571-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2003105853-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-1997010243-A1 | 2-(PYRAZOL-5-YL-OXYMETHYL)-1,2-BENZISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (US) | 1997-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082571-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | GAA 3809/4885SMN1; SMN2 1035/4885KDM4E 3526/4885 |
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | GAA 3861/4885SMN1; SMN2 1026/4885KDM4E 3949/4885 |
| US-20050256130-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | GAA 3861/4885SMN1; SMN2 1026/4885KDM4E 3949/4885 |
| US-20040162282-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | GAA 3809/4885SMN1; SMN2 1035/4885KDM4E 3526/4885 |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | GAA 3861/4885SMN1; SMN2 1026/4885KDM4E 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.